|Bid||0.0000 x 2200|
|Ask||0.0000 x 1200|
|Day's Range||3.1500 - 3.2435|
|52 Week Range||2.4600 - 26.7500|
|Beta (3Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The FDA has approved the ReStore suit from ReWalk Robotics, a soft exo-suit to assist in rehabilitative therapy for stroke survivors. ReWalk's CEO Larry Jasinski explains the tech behind the device to Yahoo Finance's Dan Roberts, Akiko Fujita, and Sibile Marcellus.
ReWalk Robotics is soaring after the manufacturer of robotic medical devices with lower limb disabilities announced that the FDA has cleared its exosuit for sale. It is the only suit with FDA clearance. Yahoo Finance's Jared Blikre join Seana Smith.
ReWalk (RWLK) delivered earnings and revenue surprises of -79.59% and -64.57%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Larry Jasinski became the CEO of ReWalk Robotics Ltd. (NASDAQ:RWLK) in 2012. First, this article will compare CEO...
Shares of ReWalk Robotics Ltd. tumbled 21% to pace all Nasdaq losers, after the maker of wearable robotic exoskeletons for use by people with limb disabilities announced a stock offering to rate about $5 million. The Israel-based company's offering comes less than a week after the stock rocketed 123%, after ReWalk said the U.S. Food and Drug Administration cleared its ReStore soft exo-suit system for sale to rehabilitation centers. The company said it was issuing 833,334 shares, which represents about 18% of the shares outstanding, to institutional investors at $6.00 each, which is 12% below Friday's closing price of $6.83. ReWalk said it also issued warrants with a term of 5 1/2 years to buy up to 416,667 shares, with an exercise price of $6.00 a share. The stock has lost 5.8% over the past three months, while the S&P 500 has gained 5.4%.
ReWalk Robotics exo-suit news for Wednesday has RWLK stock heading into orbit.Source: ReWalkReWalk Robotics (NASDAQ:RWLK) has announced that the U.S. Food and Drug Administration (FDA) has given approval to one of its new medical devices. This is the ReWalk Robotics exo-suit called "ReStore". The device will launch for a price of $28,900 and leasing options will also be available.The new ReWalk Robotics exo-suit is designed to help patients relearn how to properly walk through physical therapy. The target market for this is patients that have suffered a stroke. The difficulty of learning to walk again can result in a gait in these individuals.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIf the patients are able to make use of the new ReWalk Robotics exo-suit, they will likely learn proper walking methods. This may result in them no longer having a gait to their walk. The company says it has study results showing this and plans to release them later this year. * The 10 Best Stocks for 2019 -- So Far "This technology has broad potential, and we are currently testing additional concepts which can be applied to provide therapy and/ or mobility assistance for individuals with other diseases, such as multiple sclerosis and Parkinson's disease, and also potentially be used by a person at home and in their community," Conor Walsh, one of the leaders behind the development of the tech in the ReWalk Robotics exo-suit, said in a statement.RWLK stock was up 132% as of Wednesday afternoon, but is down 31% since the start of the year. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 6 Retailers Including Disney Agree to Ditch On-Call Scheduling * The 10 Best Stocks for 2019 -- So Far * 7 Small-Cap ETFs to Buy Now As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post ReWalk Robotics Exo-Suit News: RWLK Stock Skyrockets on FDA Approval appeared first on InvestorPlace.
As an investor, mistakes are inevitable. But really bad investments should be rare. So consider, for a moment, the...
Shares of ReWalk Robotics Ltd. rocketed 176% in very active premarket trading Wednesday, after the Food and Drug Administration cleared the company's ReStore soft exo-suit system for sale to rehabilitation centers. Volume of about 952,000 shares was already more than double the full-day average. ReWalk said in a release late Tuesday that ReStore is intended for use in treating stroke survivors suffering from walking and mobility challenges. "With a launch price of $28,900 as well as leasing options, ReStore offers cutting edge innovation with features that redefine therapy at a price that is accessable for a broader range of clinics than existing robotic technologies," said Chief Executive Larry Jasinski. "The current gait training reimbursement codes enable immediate penetration and sales growth as part of our pathway to become a break even and profitable company." The stock had tumbled 87.4% over the past 12 months, while the S&P 500 has gained 2.0%.
Stock futures extended a new strong market rally, Salesforce, Pivotal Software, Ambarella were big movers on earnings. ReWalk Robotics stock nearly tripled after the FDA OK'd its exo-suit.
The so-called exo-suit uses a system of sensors, cables and other elements to give stroke victims with mobility issues "timed bursts of assistance" while walking, the founder of Harvard University's biodesign lab Conor Walsh said. The product presents a larger market opportunity for ReWalk, which has had difficulty growing its revenue over the last five years.
The Yokneam Ilit, Israel-based company said it had a loss of $1.25 per share. The maker of wearable robotic exoskeletons that help paralyzed patients walk posted revenue of $1.6 million in the period. ...
The big shareholder groups in ReWalk Robotics Ltd. (NASDAQ:RWLK) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders...
ReWalk said a Cigna Corp (NYSE: CI) insurance beneficiary in New York became eligible to receive its ReWalk Personal 6.0 exoskeleton. The person had suffered a spinal cord injury in a motorcycle accident in 2016. Cigna revised its policy regarding coverage of exoskeleton medical devices for persons with spinal cord injury in February after having a non-coverage policy previously.
If you're interested in ReWalk Robotics Ltd. (NASDAQ:RWLK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
The Yokneam Ilit, Israel-based company said it had a loss of 10 cents per share. The maker of wearable robotic exoskeletons that help paralyzed patients walk posted revenue of $1.6 million in the period. ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many times Read More...
Larry Jasinski has been the CEO of ReWalk Robotics Ltd. (NASDAQ:RWLK) since 2012. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.
ReWalk (RWLK) delivered earnings and revenue surprises of 13.33% and -23.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?